← Leaderboards
Ramzi M. Mohammad
Wayne State University
$2,204,832
Attributed
$2,567,245
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $353.7K · FY2007–16$500K$375K$250K$125K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,567,245 · 5
By mechanism
R01$1,488,676 · 2
R21$1,078,569 · 3
Top collaborators
- Asfar S Azmi2 shared
- Chandan Reddy2 shared
Most similar at Wayne State University
Same institution · by research overlap
- Asfar S Azmi$3,644,683
- Fazlul H. Sarkar$12,841,663
Others in their field
Top investigators on “Cell Line”
- David Heimbrook · Leidos Biomedical Research, Inc.$236,973,333
- Dennis R. Burton · Scripps Research Institute$203,685,614
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$177,001,772
- John M Lachin · George Washington University$118,672,444
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- Fred M Gordin · Social And Scientific Systems, Inc.$82,802,056
Research focus
Cell LineDesignCellsSmall MoleculePharmaceutical PreparationsResistanceInhibitor/AntagonistTumorMalignant NeoplasmsProteinsApoptosisNovel TherapeuticsMalignant Neoplasm Of PancreasGenesBinding (Molecular Function)Neoplasm MetastasisMolecularIn VivoPathway InteractionsGrowthChemotherapyApoptoticInhibitory Concentration 50Event
Grant awards (13)
Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer$166,840
R21 · FY2016 · CA
Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer$199,285
R21 · FY2015 · CA
Differential Network Interrogations of Epithelial to Mesenchymal Transition$160,342
R21 · FY2014 · CA · contact PI
Differential Network Interrogations of Epithelial to Mesenchymal Transition$198,360
R21 · FY2013 · CA · contact PI
Development of Small Molecule Crm-1 Inhibitor for Pancreatic Cancer Therapy$155,382
R21 · FY2013 · CA · contact PI
Development of Small Molecule Crm-1 Inhibitor for Pancreatic Cancer Therapy$198,360
R21 · FY2012 · CA · contact PI
Specific Targets for Pancreatic Cancer Therapy$222,223
R01 · FY2011 · CA · contact PI
Specific Targets for Pancreatic Cancer Therapy$229,089
R01 · FY2010 · CA · contact PI
Specific Targets for Pancreatic Cancer Therapy$229,080
R01 · FY2009 · CA · contact PI
Specific Targets for Pancreatic Cancer Therapy$229,073
R01 · FY2008 · CA · contact PI
Specific Targets for Pancreatic Cancer Therapy$241,690
R01 · FY2007 · CA · contact PI
POTENTIATION OF 2CDA ACTIVITY IN CLL BY BRYOSTATIN 1$178,207
R01 · FY2001 · CA
POTENTIATION OF 2CDA ACTIVITY IN CLL BY BRYOSTATIN 1$159,314
R01 · FY2000 · CA